Introduction

This report investigates current trends and opportunities affecting decisions on whether or not to outsource drug discovery. Outsourcing to low cost offshore destinations such as China and India are examined in detail. The report also covers a variety of strategic collaborations, academic partnerships and outsourcing opportunities along with case studies.

Features and benefits

* Develop an informed perspective of the drug discovery process including the role of outsourcing.
* Understand the pros and cons of drug discovery outsourcing.
* Gain an understanding of the current trends and opportunities in global drug discovery outsourcing market.
* Compare the leading ten drug discovery service provider’s strategies and capabilities.
* Assess China and India as drug discovery outsourcing destinations.

Highlights

As pharma companies relax their conservatism towards drug discovery outsourcing the market, which was valued at $7.4bn in 2009 is expected to increase to $18.5bn by 2015.Among discovery outsourcing serivces, chemistry services represented the leading category of outsourced drug discovery services generating around $2.9bn in sales, accounting for a market share of 39%. Biological services accounted for $2bn with a market share of 28%, which is expected to increase in the future.The networked pharma model under which companies reduce their footprint of owned facilities in favour of a network of service providers is gaining ground. Virtual companies which outsource almost all research, manufacturing and sales activities are also expected to drive growth in the drug discovery outsourcing market.

Your key questions answered

* What are the recent trends and opportunities in global drug discovery outsourcing market?
* How will drug discovery outsourcing develop in the coming five years?* Which companies will drive the future of global drug discovery outsourcing market?
* How is the drug discovery outsourcing market evolving in China and India?
* What drug discovery outsourcing strategies are the leading pharmaceutical and biotech companies following?

To know more about this report & to buy a copy please visit:
http://www.visionshopsters.com/product/12639/The-Drug-Discovery-Outsourcing-Market.html

As the U.S. economy slid deeper into recession during 2009, coffee marketers and foodservice operators moved in the opposite direction, digging out of the trench of 2008 with a variety of strategies designed to capitalize on the fact that even upscale coffee is a relatively thrifty luxury that offers comfort during stressful times. Two success stories were the rebound of Starbucks on the foodservice side and the revitalization of the former P&G retail coffee portfolio by J M. Smucker. Although the era when the coffee market grew effortlessly through premiumization may have ended, such upscale trends as the shifts towards specialty coffee beverages, gourmet beans and ethical consumerism are still clearly in force. What’s more, there’s ample opportunity for companies to capitalize on such trends as the economy recovers—not by ignoring the tougher times or reversing strategy, but by crafting an image that’s both upscale and responsive to consumers’ stronger-than-ever demand for value.

Packaged Facts’ Coffee and Ready-to-Drink Coffee in the U.S.: The Market and Opportunities in Retail and Foodservice, 6th Edition offers a comprehensive look at this $47.5 billion market, examining both the retail and foodservice sides of the business as well as the growing overlap of the two. On the retail side, the report analyzes coffee sold for future brewing—beans and ground, and instant—as well as RTD coffee drinks (à la Frappuccinos), as well as coffee enthusiast’s new brewing method of choice: single-serve (pod) coffee. Positive upscaling trends that slowed during the weak economy will gradually regain the upper hand, the report predicts, resulting in increasing annual percentage sales gains lifting sales by 23% by 2014 to reach $58.3 billion. The report examines sales across the entire retail universe, using Information Resources, Inc. InfoScan Review data and SPINSscan data to extensively chart performance, market composition and marketer/brand performance for the mass-market and natural supermarket channels.

Comprehensive coverage is also devoted to the vast foodservice market for coffee, including the expansion of specialty drinks at such mass-market venues as McDonalds, Dunkin’ Donuts and, most recently, Burger King with its planned 2010 roll-out of Starbucks’ Seattle’s Best. Supplementing the market tracking and forecasting of previous editions, Coffee and Ready-to-Drink Coffee in the U.S.: The Market and Opportunities in Retail and Foodservice, 6th Edition pays special attention to trends in new product development, inclusive of valuable global perspective; details competitive opportunities, including via in-depth company profiles; explores winning marketing methods including Web-based activity; and provides detailed consumer profiling using Experian Simmons data for 2009.

To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/2217/Coffee-and-Ready-to-Drink-Coffee-in-the-U-S-The-Market-and-Opportunities-in-Retail-and-Foodservice-6th-Edition.html

Contact us:

Visionshopsters
Ph : 91-22-40583020
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com

Molecular diagnostics represents a revolution postponed, perhaps, but one that is now clearly underway. DNA Testing has emerged fully from research into clinical practice and becoming a dominant platform in clinical medicine.

From Emerging to Emergent Technology

Instrumentation now automates many of the sample preparation and assay steps that were formerly labor intensive. New tests are being launched all the time. At each step of the way, Kalorama Information has reported on its progress, and in this latest market research report we look at the present state of the market, and the advances that have made DNA testing routine.

Many molecular tests are CE Marked and FDA-cleared and many more are in development. The result is that molecular testing is indicated in many areas of health care.

Molecular Testing Compiled and Analyzed and Explained by a Leading Expert

Authored by lead Kalorama diagnostic analyst Shara Rosen, Kalorama Information’s World Market for Molecular Diagnostics is the most comprehensive global market report available on the emergent field of molecular diagnostics.

This report covers key platforms of molecular diagnostics, including the following :

• Polymerase Chain Reaction (PCR)
• Non-PCR Amplification Technologies, including:
  • bDNA
  • TMA
  • SDA
  • LIPA
  • NASBA
  • Invader
  • Others
• In-situ Hybridization
• Sequencing
• Microarrays
• Laser Capture Microdissection (LCM) and Tissue Arrays
• Mass Spectroscopy
• Other Molecular Platforms

This report provides market estimates and analysis for molecular diagnostics in the following categories:

• Infectious Diseases (including HIV, Hepatitis GC/Chlamydia,Organism ID, MRSA, HAI et al, Mycobacteria, TB Respiratory, Others)
• Blood Screening
• Histology
• Oncology
• Prenatal
• Coagulation
• Tissue Typing
• Inherited Diseases
• Pharmacodiagnostics

The various clinical techniques and trends are discussed from the point of view of their present and potential market impact.

Market analysis in this report covers world markets for in vitro diagnostics, with focus on the developed areas of the globe — North America and Western Europe. However public health and infectious disease are a growing global problem and where possible the report covers IVD products related to the globalization of diseases.

As part of its exhaustive coverage of nucleic acid testing, the report includes the following:

• Market Sizes and Forecasts
• Profile and Assessment of Over 140 Key Competitors
• Breakout of Molecular Diagnostic Market by Region (N. America, W. Europe, Asia, ROW)
• Medical and Technological Trends
• Discussion of Globalization of Markets and Diseases
• Information on Reimbursement of New Technologies
• Review of Novel Test Platforms
• Review of New Market Developments, Such as Consumer Genomics and Testing Services
• Discussion of Market Impact of Home Brew Tests
• Discussion of Diagnostic Biomarkers and Genetic Indicators

All market data are based on factory sales to the end user and not retail pricing or reimbursement payments. Data for the molecular test market are presented in U.S. dollar market size for categories of tests, and for specific analytes where possible. The dollar value of a market segment is directly proportional to the number of tests performed, because the cost of the instrumentation is generally buried in the per test price.

The report discusses tests and technologies that are currently available and those that are expected to take their place. Generally, current products and technologies establish the standard of care and its value to payers. Many of the assays and techniques presented in the report are expected to replace the standard of care in 2007/08, but with healthcare systems’ emphasis on cost/benefit analysis for new technologies adoption, the market value and thus penetration capabilities of newer approaches may be limited.

To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/1621/The-World-Market-for-Molecular-Diagnostics.html

Contact us:

Visionshopsters
Ph : 91-22-40583020
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com

The global market for human vaccines has experienced strong growth through 2008 and this is expected to continue through the forecast period. Growth will be fueled by new product introductions and rising usage in all regions.

This report, Vaccines 2009: Key Players, and Critical Trends in a Fast-Changing Industry), examines the market for vaccines used in humans to previous various types of disease. Sales estimates for each market segment represent global revenues and are expressed in current dollars. Estimates are provided for the historic 2008 period and forecasts are provided through 2013.

Since the last edition of this report:

• Vaccine makers are now advertising directly to the public with growing DTC budgets. The report identifies the possible market impact of this new trend.
• The economy has impacted vaccine sales with more people unable to make required out of pocket payments for vaccination.
• New categories of vaccines, such as allergy vaccines, are becoming more prominent, and have been included in our forecasts.
• Several major new products, including Wyeth’s Prevnar 13, are on the horizon. The market impact of new products is discussed.
• Two major mergers – Pfizer/Wyeth and Merck/Schering-Plough, will impact the industry and this is considered in our market analysis.

Few areas of pharmaceuticals have seen the fast-moving developments in the marketplace that the vaccine market has in 2008. Since Kalorama Information last updated Kalorama Information’s The World Market for Vaccines last year, new products and better than expected profits have transformed the vaccine marketplace. Continued sales of influenza vaccines and cervical cancer vaccines have provided a foundation for growth in the adult market. The competitive dynamics have changed with mergers, and many new products are on the way.

Kalorama Information’s exhaustive research and analysis built from interviews with key decision makers in the market includes the following:

• Review of Products in the Market
• Current World Market Size for Pediatric and Adult Vaccines
• Segmented Revenues and Forecasts to 2013 by Category
• Over 45 Charts and Tables To Make Information Accessible
• Discussion of The Current Economy and Vaccines, Immunization Refusal, Swine/Avian Flu and Other Pandemics, Delivery Sys and other Trends in the Vaccine Market
• Important Vaccines and Immunization Schedules and Statistics
• Profiles of 15 Key Vaccine Companies
• Thorough Review of the Vaccine Pipeline and Possible Impact of New Products

Who are the main players in the vaccine market? What opportunities are available for pharmaceutical companies or investors from this market? What are the potential challenges vaccine competitors must deal with? What will be the impact of the first successful cancer product? What is the significance of at least one major acquisition to affect this industry? These questions and more are tackled in this report.

Current revenues and revenue forecasts to 2013 are included for the following pediatric vaccine categories:

• DTaP & DTP Vaccines
• Hep Vaccines
• HiB Vaccines
• MMR Vaccines
• Combination Vaccines
• Pneumococcal Vaccines
• Polio Vaccines
• Varicella Vaccines
• Other Pediatric Vaccines

As well as Revenues and Forecasts to 2012 for the following adult vaccine categories:

• Influenza Vaccines
• Hepatitis Vaccines
• Pneumococcal Vaccines
• Travel, DT and other Adult Vaccines
• Cervical Cancer

This is a rapidly changing marketplace and knowledge of the R&D pipeline is essential to truly understand what is happening in vaccines. Vaccines in development are discussed in this report, including vaccines for the following conditions:

• Enterotoxigenic Escherichia coli
• Parainfluenza Virus Type 3
• Pneumococcal Vaccines
• Respiratory Syncytial Virus<
• Cancers
• Cholera
• HIV/AIDS
• Helicobacter Pylori
• Malaria
• Rabies
• Tuberculosis
• West Nile Virus

This Kalorama Information report was created with a primary research effort. Historical information for this report was gathered from a wide variety of published sources including company reports and filings, government documents, legal filings, trade journals, newspapers and business press, analysts’ reports and other sources. Interviews with company representatives and other experts were conducted to capture the perspectives from industry participants’ point of view and assess trends, and form the basis of the forecasting and competitive analysis.

To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/1645/Vaccines-2009-World-Market-Analysis-Key-Players-and-Critical-Trends-in-a-Fast-Changing-Industry.html

Contact us:

Visionshopsters
Ph : 91-22-40583020
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com

Since Kalorama Information last updated our comprehensive market report on cancer testing, changes in the industry abound. Developments that were novel two years ago such as the commercialization of service products , PGx testing and tissue microarrays are showing an increased presence. Some companies who promised much in the past have not produced results. And new entrants have entered the field.

These changes and more are addressed in Kalorama Information’s Worldwide Market for Cancer Diagnostics, 4th. Edition. This report authored by Kalorama Diagnostic Analyst Shara Rosen, contains detailed market data on the following IVD segments for their use in cancer diagnostics:

• Histology/Cytology
• Immunoassays
• Flow Cytometry
• Rapid Tests
• Molecular Assays
• Tissue Arrays
• Circulating Tumor Cells
• Pharmacodiagnostics

Diagnostic tests for effective cancer screening are obviously needed more than ever. As cancer becomes more treatable, diagnostics are finding multiple expanded roles, including pharmacodiagnostics for matching the targeted treatment to the patient and ongoing disease monitoring as treatable cancer enters the realm of the chronic disease. Kalorama Information’s Worldwide Market for Cancer Diagnostics, 4th Edition represents the fourth time Kalorama has engaged in an exhaustive study on the status of this important diagnostic market. Among the market data provided in this report, readers will find:

• Immunoassay Lab Based Cancer Test Sales
• Pap Smear Testing Volumes
• World Cancer Statistics
• POC Tests
• DNA Reagents for Cancer Testing
• CTC Testing Markets
• Biochip Innovations
• New Companies with Novel Approaches
• “Laggard” Companies Who Have Not Met Expectations
• Major Protein and Molecular Markers Used in Tissue Staining
• Biomarkers Under Investigation
• Acquisitions and Mergers
• Status of PGx Testing
• Microarray Markets in Clinical Labs
• Lists of Vendors and Major Products
• Unmet Needs of the Marketplace

This report includes market analysis of the following screening tests: The Cancer Profile, CTC, Fecal Occult Blood, PSA, H. pylori, IHC, ISH As well as tests for specific cancers:

• Bladder Cancer
• Breast Cancer
• Cervical Cancer
• Colon Cancer
• Lung Cancer
• Ovarian Cancer
• Prostate Cancer

This latest edition of Kalorama Information’s study takes a fresh look at all of these developments both qualitatively and quantitatively. The report provides revenue and growth forecasts through 2014 and, as in the previous edition, analyzes the market in two ways:

• Tests for specific cancers, and
• Cancer tests in specific IVD segments

This allows the reader to match his or her own situation to the market at large.

In addition to extensive reviews of products on the market and in development in each segment, the report provides detailed company profiles.

Top Tier Companies

• Abbott Diagnostics
• Beckman Coulter Inc.
• Becton, Dickinson and Company (BD)
• bioMerieux Inc.
• Bio-Rad Laboratories Inc.
• Dako A/S
• Fujirebio Diagnostics, Inc.
• Gen-Probe Inc.
• Hologic, Inc.
• Inverness Medical Innovations
• Ortho Clinical Diagnostics
• QIAGEN N.V.
• Roche Diagnostics
• Siemens Medical Solutions Diagnostics
• Sysmex Corporation

To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/2216/The-Worldwide-Market-for-Cancer-Diagnostics-4th-Edition.html

Contact us:

Visionshopsters
Ph : 91-22-40583020
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com

Kalorama Information publishes its third edition of this detailed report on the long term care industry at a time of growth but also change and concern for the long term care industry. The economy has challenged the business strategies of key players, while the recent healthcare legislation introduces changes that may affect revenues. These twin challenges are addressed in The Long-Term Care Market: Nursing Homes, Home Care, Hospice Care, and Assisted Living The report provides an in-depth examination of the market for long-term care today. The following segments are broken out in detail: This report covers the most important segments of the long term care industry, each of which provide medical care and/or assistance with the activities of daily living (ADLs) on an ongoing basis:

• Nursing care;
• Home Care;
• Hospice Care;
• Assisted Living.

Excluded are markets that address temporary care needs such as physical or mental rehabilitation. Residential living programs and facilities that do not generally provide care such as retirement communities.

For each of the segments of long term care the report provides:

• Market Size and Forecast
• Number of Facilities/Providers and Growth Trends
• Patient Statistics
• Forms of Payment and Reimbursement Levels
• Trends Affecting the Marketplace
• Competitors and Competitive Analysis

Sales estimates for each market segment represent U.S. revenues and are expressed in current dollars. Estimates are provided for the historic 2005 to 2009 period and forecasts are provided through 2015.

As part of the report’s analysis of the state of the industry, the report covers the Recent Healthcare Reform and its Impact on Nursing Homes and the Effects of the Economy Other issues and trends discussed in the report include:

• Medicare & Health Care Reform
• Patient Dumping
• Quality of Care
• Federal Quality Improvement Initiatives
• State Quality Improvement Initiatives
• Legal Actions
• Safety
• Aging of the Population
• Marital and Living Arrangements
• Geographic Concentrations
• Certification and Accreditation
• Fees and Payment
• Long Term Care Insurance
• Cost of Coverage and Affordability
• Staffing and Human Resources
• Building of New Facilities

Historical information for this report was gathered from a wide variety of published sources including company reports and filings, government documents, legal filings, trade journals, newspapers and business press, analysts’ reports and other sources. Interviews with company representatives were conducted to capture the perspectives from industry participants’ point of view and assess trends, and form the basis of the forecasting and competitive analysis.

As part of its coverage of the industry, the following long term care companies were profiled in this report:

• Apria Healthcare Group Inc./ Blackstone Group
• Brookdale Senior Living
• Emeritus Corporation
• Extendicare, Inc.
• Genesis Healthcare
• Golden Living
• Manor Care, Inc.
• Sun Healthcare Group Inc.
• Sunrise Senior Living Inc.

To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/3346/Long-Term-Care-Market-Nursing-Homes-Home-Care-Hospice-Care-and-Assisted-Living.html

Contact us:

Visionshopsters
Ph : 91-22-40583020
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com

In seven best-selling editions, Shara Rosen has provided a total view of every aspect of the market for in vitro diagnostic (IVD) testing in one complete volume. The report, The Worldwide Market for In Vitro Diagnostic Tests, stands as a testament to the Kalorama methodology. Real industry knowledge combined with an exhaustive review of the medical, business, and company literature. Market numbers for business planning matched with a discovery of the trends that are impacting the industry. A realistic forecast five years into the future for companies already participating in or considering entry into this growing industry. The idea behind Kalorama’s unique report is that the entire market can be captured in one volume and business planners can use it as a key reference. Published every two years, this volume includes coverage of the most important aspects of all of the major segments of clinical lab testing, including:

• Point of Care (POC), (Professional and Self-Testing)
• Core Lab (General Chemistries, Workstations, Analyzers)
• Immunoassays (Blood Gases, Urinalysis, Critical Care)
• Molecular Assays (Infectious Disease, Blood Screening, Inherited Diseases, Oncology, Pharmacodiagnostics, Tissue Typing, Prenatal)
• Hematology
• Coagulation (Lab-Based, POC, Genetic Markers)
• Microbiology and Virology
• Blood Banking (Grouping, Immunoassay Screens, NAT Screens)
• Histology and Cytology (Pap, ISH, IHC, traditional non-pap, HPV)

For each of these sections, Shara Rosen reviews the key products dominating the market segment, the innovations that are occurring, trends that are impacting the segment. Market size, and forecast and market share are provided; and discussion of regional numbers of the segment is provided where possible. Changes in technology development, regulatory and reimbursement issues, clinical care, and business environments are discussed. Current market is provided for 2009; projections are made through 2014.

Kalorama Information’s Report – ‘The Bible of the IVD Industry’

Many of the top IVD companies use this product for business planning, which means that this volume can provide a uniform standard for in vitro diagnostic market numbers. These are the numbers that it is very likely competitive companies will be using in their planning.

This 900+ page edition greatly expands coverage of the field and tracks the most important developments.

A Global Report

IVD is a worldwide business. While the US is a large healthcare market, much of the dynamism occurs in other areas. Many of the most interesting developments are occurring in emerging markets. As part of its coverage, the report breaks down the entire IVD market for the following regions.

• North America
• Europe (EU)
• Eastern Europe
• South America
• Asia (China and India as subsegments)
• Rest of World

A Report Designed for a Changing Industry

In this seventh edition of The Worldwide Market for In Vitro Diagnostic Tests Kalorama Information has reorganized the presentation of the IVD market in a manner that better reflects how the industry has evolved.

To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/6013/The-Worldwide-Market-for-In-Vitro-Diagnostic-Tests-7th-Edition.html

Contact us:

Visionshopsters
Ph : 91-22-40583020
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com

This profile is the essential source for top-level energy industry data and information. The report provides an overview of each of the key sub-segments of the energy industry in France. It details the market structure, regulatory environment, infrastructure and provides historical and forecasted statistics relating to the supply/demand balance for each of the key sub-segments. It also provides information relating to the crude oil assets (oil fields, refineries, pipelines and storage terminals) in France. The report also analyses the fiscal regime relevant to the crude oil assets in France and compares the investment environment in France with other countries in the region. The profiles of the major companies operating in the crude oil sector in France together with the latest news and deals are also included in the report.

Scope

• Historic and forecast data relating to production, consumption, imports, exports and reserves are provided for each industry sub-segment for the period 1996-2020.
• Historical and forecast data and information for all the major oil fields, refineries, pipelines and storage terminals in France for the period 2000-2013.
• Operator and equity details for major crude oil assets in France.
• Key information relating to market regulations, key energy assets and the key companies operating in the France’s energy industry.
• Detailed information on key fiscal terms (such as rents, bonuses, royalty, cost recovery, profit oil, petroleum and corporate taxes) pertaining the geography is also provided. A sample calculation detailing how fiscal terms apply to a typical asset in the regime is included.
• Information on the top companies in the France including business description, strategic analysis, and financial information. Key companies covered include TOTAL S.A, Exxon Mobil Corporation,
• Product and brand updates, strategy changes, R&D projects, corporate expansions and contractions and regulatory changes.
• Key mergers and acquisitions, partnerships, private equity and venture capital investments, and IPOs.

Reasons to buy

• Gain a strong understanding France’s oil market.
• Facilitate market analysis and forecasting of future industry trends.
• Evaluate the attractiveness of this geography for oil investment in the light of government policies and the fiscal environment.
• Facilitate decision making on the basis of strong historic and forecast production, reserves and capacity data.
• Understand the policies and fiscal terms, and their impact on contractor’s profits from upstream oil assets.
• Assess your competitor’s major crude oil assets and their performance.
• Analyze the latest news and financial deals in the oil sector in France.
• Develop strategies based on the latest operational, financial, and regulatory events.
• Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the market.
• Identify and analyze the strengths and weaknesses of the leading companies the French oil market.

Companies Mentioned

Gaz de France
TOTAL S.A.
Exxon Mobil Corporation

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3158/France-Oil-Markets-2010-Investment-Opportunities-Market-Analysis-and-Forecasts-to-2020.html
———————————————-

Medical equipment report offering, “Belgium Patient Monitoring Market Outlook to 2016” provides key market data on the Belgium patient monitoring market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within seven market categories – Multiparameter Patient Monitoring, Remote Patient Monitoring, Patient Monitoring Leads and Electrodes, Non-invasive Blood Pressure Monitors, Neonatal Monitors, Fetal Monitors and Micro-electromechanical Systems. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

• Market size and company share data for seven patient monitoring market categories – Multiparameter Patient Monitoring, Remote Patient Monitoring, Patient Monitoring Leads and Electrodes, Non-invasive Blood Pressure Monitors, Neonatal Monitors, Fetal Monitors and Micro-electromechanical Systems.
• Annualized market revenues (USD million), volume (units) and average price (USD) data for each of the segments and sub-segments within seven market categories. Data from 2002 to 2009, forecast forward for 7 years to 2016.
• 2009 company shares and distribution shares data for each of the seven market categories.
• Global corporate-level profiles of key companies operating within the Belgium patient monitoring market.
• Key players covered include Philips Healthcare, GE Healthcare, Draegerwerk AG & Co. KGaA, OMRON HEALTHCARE Co., Ltd., Nihon Kohden Corporation, Mindray Medical International Limited and Medtronic, Inc.

Reasons to buy

• Develop business strategies by identifying the key market categories and segments poised for strong growth.
• Develop market-entry and market expansion strategies.
• Design competition strategies by identifying who-stands-where in the Belgium patient monitoring competitive landscape.
• Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
• What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

Companies Mentioned

Philips Healthcare
GE Healthcare
Draegerwerk AG & Co. KGaA
OMRON HEALTHCARE Co., Ltd.
HARTMANN GROUP
A&D Medical / LifeSource
3M Health Care
Welch Allyn Inc.
The Dixion Company
Terumo Corporation
St. Jude Medical, Inc.
Spacelabs Healthcare, Inc.
Siemens Healthcare
Schiller AG
Rossmax International Ltd.
OSI Systems, Inc.
Nihon Kohden Corporation
Mindray Medical International Limited
Microlife Corporation
Mennen Medical Ltd.
Medtronic, Inc.
Larsen & Toubro Medical Equipment & Systems
GE Sensing & Inspection Technologies
Fukuda Denshi Co., Ltd.
Edwards Lifesciences Corporation
Edan Instruments, Inc.
Criticare Systems, Inc.
Covidien plc
CONMED Corporation
LifeWatch AG
Boston Scientific Corporation
BIOTRONIK SE & Co. KG
Bionet Co.,Ltd.
AViTA Corporation
Ambu A/S
Patient Monitoring Market Pipeline Products

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3143/Belgium-Patient-Monitoring-Market-Outlook-to-2016.html
———————————————-

“Dysmenorrhea – Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global dysmenorrhea market. The report identifies the key trends shaping and driving the global dysmenorrhea market. The report also provides insight into the prevalent competitive landscape and the emerging players expected to bring a significant shift in the positioning of the existing market leaders. Most importantly, the report provides valuable insight into the pipeline products within the global dysmenorrhea sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts
The global dysmenorrhea therapeutics market was valued at $1.7 billion in 2009. It is expected to grow at a Compound Annual Growth Rate (CAGR) of 3.9% by 2016. This slow growth is primarily attributed to due to the lack of diagnostic techniques, disease awareness and the poor safety and efficacy profiles of the existing therapies. The current competitive landscape consists of only generics and off-label therapies, none of which have a dominant position. The current emphasis has been on treating the symptoms of the disease without providing an absolute cure.

Scope

The scope of the report includes:
- Annualized global dysmenorrhea market revenues data from 2001 to 2009, forecast forward for seven years to 2016.
- Geographies covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France and Japan.
- Pipeline analysis data providing a split across different phases by the mechanism of action being developed and emerging trends. Key classes of mechanism of action include prostaglandin synthetase inhibitors and COX-2 inhibitors.
- Analysis of the current and future market competition in the global dysmenorrhea market. Key market players covered are China Aoxing Pharmaceutical Company, Vantia Therapeutics, Columbia Laboratories, Merck and Bayer Schering Pharma AG.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessments, market characterization, the unmet needs and the implications for the future market associated with dysmenorrhea.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through a review of the pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global dysmenorrhea market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global dysmenorrhea market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain the competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present the maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global dysmenorrhea market landscape? – Identify, understand and capitalize.

Companies Mentioned

China Aoxing Pharmaceutical Co., Inc
Merck
Vantia Therapeutics
Bayer Schering Pharma
Columbia Laboratories

For more information on the report, kindly visit :
http://www.visionshopsters.com/product/3104/Dysmenorrhea-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html
———————————————-